In this edition of The Motley Fool's "Ask a Fool" series, Motley Fool analysts Jason Moser and Brendan Mathews take a question from a reader who asks:
I bought Organovo (NYSEMKT:ONVO) at the end of April after they announced demand for their product had increased. Shares have gone up considerably since then. Can you discuss if this is sustainable or just a bubble?
Organovo is a very interesting company in that it provides 3-D bioprinting technology that allows customers to print human tissue for use in drug testing. It’s a fascinating concept, and one with potentially major implications, as it could make the drug approval process potentially much better because it would give companies a better idea whether to pursue an idea, or move on to the next one without wasting additional funds.
Investors need to note that this is a development stage company, meaning it relies heavily on grants, partnerships, and public markets for funding, and there are no guarantees it will succeed. They made mention of the fact that they have interest from a number of different parties, including big pharma and biotech players.
However, Organovo isn’t the only game in town, so it remains to be seen if what they provide is enough of a differentiator. Earnings results out today have sent shares lower, due, in part, to lower sales and higher costs. Jason notes that this isn’t a company that he would be interested in. For those who are, he recommends that it should only be a small allocation in the context of a well-diversified portfolio.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier, and more accurately, than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not only how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you will need The Motley Fool’s new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.
Brendan Mathews has no position in any stocks mentioned. Jason Moser has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.